Echo Therapeutics Inc

Echo Therapeutics — Jefferies 2013 Global Healthcare Conference

16 slides from Echo Therapeutics's conference presentation, Jun 7, 2013

  1. Slide 1: Echo Therapeutics, June 2013

    @©echo THERAPEUTICS June 2013 \)

  2. Slide 2: Forward-looking statements

    Any statements contained in this presentation that do not describe historical facts may constitute forward- looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations of Echo Th

  3. Slide 3: Company highlights

    = Prelude® SkinPrep = Enabling technology for painless and significantly enhanced skin permeation = Symphony® CGM System = Non-invasive, wireless, continuous blood glucose monitoring system = Multiple pilot studies in glucose monitoring conducted = Significant market opportunity = $3—4 billion marke

  4. Slide 4: Management team and key advisors

    Name Patrick Mooney, M.D. tle Chairman and CEO Past Experience Chairman and CEO, Aphton Corp. Senior Biotech Analyst, Thomas Weisel Partners Chris Schnittker, CPA ‘SVP & CFO Micromet, Cytogen & Sanofi Aventis, ‘Samir Farah VP Research & Development _| Philips Healthcare, Abbott Diabetes Care David W

  5. Slide 5: Glucose over time

    Glucose - Time @©echo [=| THERAPEUTICS

  6. Slide 6: Three Approaches to CGM

    Three Approaches to CGM Transdermal Subcutaneous Intravenous Degree of invasiveness echo

  7. Slide 7: Symphony vs. Subcutaneous Sensors

    Symphony" vs. Subcutaneous Sensors Symphony

  8. Slide 8: Prelude SkinPrep technology

    = Removes outer layer of dead skin called stratum corneum = Patented feedback control algorithm designed for ‘safe and precise skin permeation = Increased permeability allows both analyte extraction and drug delivery «echo oe THERAPEUTICS

  9. Slide 9: Symphony CGM System components

    Prelude® SkinPrep + Removes stratum comeum for accurate measurement of glucose + Patented feedback control mechanism for optimal skin permeation Transdermal Glucose Sensor + Electro-chemical glucose sensor plus short-range wireless transmitter + Affixed to area prepared with Prelude Wireless Remote

  10. Slide 10: TGC Protocols in US hospitals

    TGC (tight glycemic control) Protocols in 80% of U.S. hospitals 6,000 hospitals in the U.S. 120,000 critical care beds in U.S. Hospitals currently spend up to $200/day in TGC" Nurses spend 2 hours/day per patient for TGC? Critical care market opportunity $1bn - $2bn Hileman D. Semin Thorac Cardiovas

  11. Slide 11: TGC Protocols in European hospitals

    TGC Protocols in 70%-90% of European hospitals‘? 60,000 critical care beds in Europe? Nurses spend 1.4 hours/day per patient for TGC 4 Critical care CGM market opportunity of $500 million Additional hospital non-critical care market opportunity Gakuba et al. ESICM poster. 2011 ‘Sharpe et al, ESICM p

  12. Slide 12: Global glucose monitoring market and diabetes use

    = Global glucose monitoring market is ~$12 billion and underpenetrated = Diabetes Consumer Use = 350 million with diabetes worldwide = Outpatient CGM market opportunity greater than $1.5 billion and growing = Potential Benefits of Symphony: = Improved glucose control = Access to real-time values, tr

  13. Slide 13: Future development opportunities

    = Hospital use beyond ICU = Longer duration sensor life = Integration with vital signs monitor = Integration with insulin dosing software = Integration with hospital information systems = Outpatient diabetes = Integration with insulin pump = New mobile receiver = Geographic expansion beyond North Am

  14. Slide 14: Multiple pilot studies completed

    = Multiple pilot studies completed that suggest: = Symphony performance consistent and effective at monitoring glucose = Symphony accuracy appears superior to approved glucometers = Symphony reliable during studies = No safety concerns identified «echo i THERAPEUTICS

  15. Slide 15: Pilot study results and MARD

    Study Date Patienttype # Patients Data MARD* IMR 07/2008 THT2 10 1258 138 MRI 11/2009 TaT2 10 820 128 MR it 9/2011 Heatthy 12 1638 105 99.5" MR IV 12/2011 T4T2 20 2685 126 96.9" Hospital Critical Care Pilot . Suns 5/2012 Critical Care 15 601 123 99.6 Hospital Critical Care Pilot . Leen 08/2012 Criti

  16. Slide 16: Regulatory milestones: Europe and United States

    Europe United States v Complete ISO 13485 Audit * FDA Pre-Submission v Initiation of CE Mark Trial * FDA Meeting = File CE Mark Technical File = Initiation of Pivotal Trial = Gain CE Marking = File PMA = Launch Initial EU Countries = Gain PMAApproval = Launch Additional EU Countries = U.S. Launch Gl

Echo Therapeutics — Jefferies 2013 Global Healthcare Conference on 6ix